Clinical trials: Prednisone, completed
Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00049595
- Testing
- bleomycin sulfate, filgrastim, pegfilgrastim
- Where
- 140 sites in Australia, Belgium and 11 more
- Volunteers
- 552 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Lymphoblastic Leukemia
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Current therapeutic protocols for adult ALL consider MRD together with the baseline risk factors (age, WBC count, immunophenotype, cytogenetics) and speed in response to therapy for treatment decisions.
- Trial name
- LAL-AR/2003 (NCT00853008)
- Testing
- Vincristine, Daunorubicin, Prednisone
- Where
- 38 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Rheumatoid Arthritis
A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis
The overall objective of the study is to assess the effectiveness of switching from immediate-release prednisone (conventional) therapy to delayed-release prednisone (RAYOS) in patients with moderately to severely active…
- Trial name
- SUNRAY (NCT02287610)
- Testing
- RAYOS (delayed-release prednisone)
- Volunteers
- 75 people
- Sponsor
- Amgen
Asthma
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)
The purpose of this study is to test the safety of DULERA. DULERA is a pressurized metered-dose inhaler (MDI) that contains two drugs combined, namely mometasone and formoterol in a single inhaler.
- Trial name
- SPIRO (NCT01471340)
- Testing
- Mometasone Furoate/Formoterol MDI 100/5 mcg, Mometasone Furoate/Formoterol MDI 200/5 mcg, Mometasone Furoate MDI 100 mcg
- Volunteers
- 11,744 people
- Sponsor
- Organon and Co
Prostate Cancer
Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)
This is a two-arm, randomized Phase II study of intermittent chemotherapy with and without GM-CSF. All patients will receive six 21-day cycles of docetaxel 75 mg/m2 on Day 2 of each cycle and 5 mg prednisone twice a day on Days…
- Trial name
- NCT00488982
- Testing
- Docetaxel, Docetaxel and GM-CSF
- Where
- 4 sites in United States
- Volunteers
- 125 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with abiraterone and steroids.
- Trial name
- NCT01685268
- Testing
- AT13387, abiraterone acetate, Prednisone
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 49 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Metastatic Castration-resistant Prostate Cancer
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
The VIABLE study sought to confirm the hypothesis that the combination of docetaxel with DCVAC/PCa followed by a maintenance therapy with DCVAC/PCa would improve overall survival in patients with metastatic castration-resistant…
- Trial name
- VIABLE (NCT02111577)
- Testing
- DCVAC/PCa
- Where
- 177 sites in United States, Austria and 20 more
- Volunteers
- 1,182 people
- Sponsor
- SOTIO a.s.
Wet Age-related Macular Degeneration
AAVCAGsCD59 for the Treatment of Wet AMD
Patients with treatment naive wet AMD will receive an intravitreal anti-VEGF injection at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7.
- Trial name
- NCT03585556
- Testing
- Intravitreal anti-VEGF, Intravitreal AAVCAGsCD59, Oral prednisolone
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
RATIONALE: Reducing the amount of drugs used to prevent transplant rejection may help a person's body kill tumor cells. Giving biological therapy, such as interferon alfa, which may interfere with the growth of cancer cells, or…
- Trial name
- NCT00002657
- Testing
- bleomycin sulfate, recombinant interferon alfa, cyclophosphamide
- Where
- 86 sites in United States
- Volunteers
- 20 people
- Sponsor
- SWOG Cancer Research Network
Immune Thrombocytopenic Purpura
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
This study is designed to compare the efficacy and safety of higher doses of Rituxan with a regimen combining standard doses of Rituxan + CVP in patients with chronic ITP who did not respond to or relapsed after standard doses of…
- Trial name
- NCT00774202
- Testing
- Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Weill Medical College of Cornell University
Lymphoma, Non Hodgkin
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
This multicenter, open-label, dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of polatuzumab vedotin in combination with rituximab or obinutuzumab, cyclophosphamide…
- Trial name
- NCT01992653
- Testing
- Cyclophosphamide, Doxorubicin, Obinutuzumab
- Where
- 11 sites in United States, France
- Volunteers
- 85 people
- Sponsor
- Genentech, Inc.
Lymphoma
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00039195
- Testing
- filgrastim, rituximab, carboplatin
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Graft-versus-host Disease
Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
In this study patients with moderate to severe chronic graft-versus-host disease will be treated with a combination of prednisone and everolimus.
- Trial name
- PredEver first (NCT01862965)
- Testing
- PredEver
- Where
- 6 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Prostate Cancer
Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca
The purpose of the study is to test genes for BRCAness(BRCA[BReast CAncer] gene) Studying these genes could help predict which patients would benefit from treatment with satraplatin, a medication being used for subjects who have…
- Trial name
- NCT01289067
- Testing
- Satraplatin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- William K. Oh
Asthma
Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)
This study compares the 12-week efficacy and 24-week safety of mometasone furoate/formoterol fumarate (MF/F) 100/10 mcg and mometasone furate (MF) 100 mcg, both administered twice daily (BID) via metered-dose inhaler (MDI) in…
- Trial name
- NCT02741271
- Testing
- MF MDI 100 mcg BID (Open Label), MF/F MDI 100/10 mcg BID, MF MDI 100 mcg BID
- Volunteers
- 181 people
- Sponsor
- Organon and Co
Chronic Graft Versus Host Disease
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.
- Trial name
- iNTEGRATE (NCT02959944)
- Testing
- ibrutinib, Prednisone
- Where
- 102 sites in United States, Australia and 13 more
- Volunteers
- 193 people
- Sponsor
- Pharmacyclics LLC.
Metastatic Hormone Refractory Prostate Cancer
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer.
- Trial name
- NCT00411528
- Testing
- Patupilone, prednisone, docetaxel
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism
This study will investigate the effect of a single dose of PF-04171327 or prednisone on calculated measures of glucose tolerance and insulin resistance by using a modified oral glucose tolerance test
- Trial name
- NCT01199900
- Testing
- PF-04171327, Prednisone
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lymphoblastic Leukemia, Acute
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
- Trial name
- NCT00137111
- Testing
- Prednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 501 people
- Sponsor
- St. Jude Children's Research Hospital
Hodgkin´s Lymphoma
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.
- Trial name
- NCT00284271
- Testing
- Cyclophosphamide, Adramycin, Procarbacine
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- University of Cologne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.